AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Dec 28, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2006.102962v1
97/2/199-a    most recent
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suba, E. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Suba, E. J.
Related Collections
Right arrow Global Health
Right arrow Screening
Right arrow Cancer
Right arrow Women's Health
February 2007, Vol 97, No. 2 | American Journal of Public Health 199-200
© 2007 American Public Health Association
DOI: 10.2105/AJPH.2006.102962

LETTER

SUBA RESPONDS

Eric J. Suba, MD

The author is with the Viet/American Cervical Cancer Prevention Project, San Francisco, Calif, and with Kaiser Permanente Medical Center, San Francisco.

Correspondence: Requests for reprints should be sent to Eric J. Suba, MD, Kaiser Permanente Medical Center, 1200 El Camino Real, South San Francisco, CA 94080 (e-mail: eric.suba@kp.org).

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

"Feasibility" refers to that which is possible, in addition to that which is operational, successful, or sustained. Papanicolaou screening is feasible anywhere cervical screening is appropriate, because it is not appropriate to screen for cancer among communities without access to curative treatment services, and because communities with access to curative treatment will also have access to cytology laboratories. Papanicolaou screening is the only preventive option currently available for public sector control of cervical cancer in developing countries.1 Because future screening programs based on alternative screening tests will require cytology as an essential triage component, visual inspection with acetic acid (VIA), . . . [Full Text]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Public Health Association